The Muscle Invasive Bladder Cancer (MIBC) drugs in development market research report provides comprehensive information on the therapeutics under development for Muscle Invasive Bladder Cancer (MIBC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Muscle Invasive Bladder Cancer (MIBC). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Muscle Invasive Bladder Cancer (MIBC) and features dormant and discontinued products.
GlobalData tracks 39 drugs in development for Muscle Invasive Bladder Cancer (MIBC) by 33 companies/universities/institutes. The top development phase for Muscle Invasive Bladder Cancer (MIBC) is phase ii with 23 drugs in that stage. The Muscle Invasive Bladder Cancer (MIBC) pipeline has 37 drugs in development by companies and two by universities/ institutes. Some of the companies in the Muscle Invasive Bladder Cancer (MIBC) pipeline products market are: Johnson & Johnson, Bristol-Myers Squibb and Merck.
The key targets in the Muscle Invasive Bladder Cancer (MIBC) pipeline products market include Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, and Tubulin.
The key mechanisms of action in the Muscle Invasive Bladder Cancer (MIBC) pipeline product include Programmed Cell Death Protein 1 Antagonist with ten drugs in Phase III. The Muscle Invasive Bladder Cancer (MIBC) pipeline products include 13 routes of administration with the top ROA being Intravenous and 12 key molecule types in the Muscle Invasive Bladder Cancer (MIBC) pipeline products market including Monoclonal Antibody, and Small Molecule.
Muscle Invasive Bladder Cancer (MIBC) overview
Muscle invasive bladder cancer (MIBC) is a type of bladder cancer that has grown into the muscle wall of the bladder, making it more likely to spread to other parts of the body. It accounts for about 25% of bladder cancers and has a poor prognosis. The main risk factor for MIBC is smoking, but other factors such as family history, workplace exposure to carcinogens, and prior radiation therapy can also increase the risk. The most common symptom of MIBC is blood in the urine, which can be painless or accompanied by other urinary problems. Diagnosis of MIBC involves urine tests, cystoscopy, biopsy, and imaging tests. Treatment options for MIBC include surgery to remove the bladder or part of it, chemotherapy, radiation therapy, or a combination of these. Early detection and proper management are important for better outcomes.
For a complete picture of Muscle Invasive Bladder Cancer (MIBC)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
